

Nordion exits Selective Gas Extraction (SGE) Mo-99 project

KANATA, ON – April 4, 2018 – Nordion, a Sotera Health company, and a leading global provider of gamma technologies and medical isotopes, today announced that the company is withdrawing from a project to develop a new research reactor-based source of molybdenum 99 (Mo-99).

The project, which involved a collaboration between Nordion, General Atomics (GA) and the University of Missouri Research Reactor (MURR), would have used Selective Gas Extraction (SGE) technology to produce Mo-99 on a commercial scale.

“Mo-99 has been a core product in the Medical Isotopes business for 60 years, and Nordion has long been recognized as a world leader in the business,” says Kevin Brooks, President of Nordion. “But market conditions have changed, so our focus will shift to other products like cyclotron isotopes, contract manufacturing of radiopharmaceuticals and specialty medical devices.”

While Nordion remains confident of the viability of the SGE technology, the project has been confronted with delays and cost increases that have increased the project’s commercial risk, leading the company to trigger the termination.

“It’s important to recognize the accomplishments of the project team, including our project partners GA and MURR, and especially our employees at Nordion, who met and defeated numerous challenges,” said Kevin Brooks. “While this closes the chapter on Mo-99, our facilities, people and expertise position us well in any area of the business we choose to enter.”

About Nordion

Nordion, a Sotera Health company, is a leading provider of gamma technologies and medical isotopes used for the prevention, diagnosis and treatment of disease and infection. Nordion’s products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion supplies products to more than 40 countries around the world, and is committed to its mission of *Safeguarding Global Health*[™]. Learn more about Nordion at www.nordion.com.

About Sotera Health:

[Sotera Health LLC, along with its business entities](#), is the world’s leading, fully integrated protector of global health. With over 500 years of combined scientific expertise, the company ensures the safety of healthcare by providing mission-critical services to the medical device, pharmaceutical, tissue and food industries. Sotera Health operates more than 61 facilities in 13 countries. The company has over 2,800 employees globally and touches the lives of more than 180 million people around the world each year. Sotera Health serves more than 5,000 customers worldwide including 75 of the top 100 medical device manufacturers. Sotera Health goes to market through its three best-in-class companies – [Nelson Labs](#)[™], [Nordion](#)[®] and [Sterigenics](#)[®] - with the mission of ensuring the safety of healthcare each and every day.

Sotera Health LLC is owned by private equity firms Warburg Pincus and GTCR. Learn more about **Sotera Health** at soterahealth.com, about **Nelson Labs** at nelsonlabs.com, about **Nordion** at nordion.com and about **Sterigenics** at sterigenics.com.

Contact: Paul Monlezun
Public Affairs Advisors
613-222-7184
paul.monlezun@publicaffairsadvisors.com